Utilization and safety of digoxin in patients with chronic heart failure and atrial fibrillation with rapid ventricular rate

Back

ESC Premium Access

Utilization and safety of digoxin in patients with chronic heart failure and atrial fibrillation with rapid ventricular rate

Session: Drug therapy for heart failure: what is new?

Topic: Pharmacotherapy

Speaker: Doctor K. Berge (Oslo, NO)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Doctor Kristian Berge

Akershus University Hospital, Oslo (Norway)

0 follower

8 more presentations in this session

Effects of Sacubitril/Valsartan on all-cause hospitalizations in heart failure: participant-level pooled analysis of PARADIGM-HF and PARAGON-HF

Speaker: Doctor H. Lu (Boston, US)

Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers population

Speaker: Professor M. Crespo-Leiro (A Coruna, ES)

Efficacy of sotagliflozin by diabetes duration: a secondary analysis of SCORED

Speaker: Doctor R. Aggarwal (Boston, US)

Effects of dapagliflozin in heart failure according to duration of type 2 diabetes: a patient-level meta-analysis of DAPA-HF and DELIVER

Speaker: Doctor J. Butt (Copenhagen, DK)

Long-term follow-up of the TRED-HF trial

Speaker: Miss L. Cheng (London, GB)

Access the full session

Drug therapy for heart failure: what is new?

Speakers: Doctor K. Berge, Doctor H. Lu, Professor M. Crespo-Leiro, Doctor R. Aggarwal, Doctor J. Butt...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources